Difference between revisions of "Stub"
Jump to navigation
Jump to search
m (→TG+Bev) |
m |
||
| Line 1: | Line 1: | ||
| + | {{TOC=2}} | ||
Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon. This page is primarily to drive the [[Ontology]]. | Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon. This page is primarily to drive the [[Ontology]]. | ||
Revision as of 19:48, 29 July 2020
Template:TOC=2 Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon. This page is primarily to drive the Ontology.
Ixabepilone & Bevacizumab
| back to top |
Regimen
Chemotherapy
Targeted therapy
TG+Bev
| back to top |
TG+Bev: Taxotere (Docetaxel), Gemcitabine, Bevacizumab
Regimen
Chemotherapy
Targeted therapy
TX+Bev
| back to top |
TX+Bev: Taxotere (Docetaxel), Xeloda (Capecitabine), Bevacizumab